[6] Primary hyperoxaluria type 1 is a rare disease in which urine oxalate is too high, which over time can harm the kidneys.
[3] Nedosiran is indicated to lower urinary oxalate levels in people nine years of age and older with primary hyperoxaluria type 1 and relatively preserved kidney function.
[1][3] The US FDA approved nedosiran based on evidence from a clinical trial which included 29 participants with primary hyperoxaluria type 1.
[3] Nedosiran was evaluated in one clinical trial of 29 participants with primary hyperoxaluria type 1 who were nine years of age and older.
[3] The benefit of nedosiran was assessed by measuring the amount of oxalate in the urine and comparing it to placebo.